La chaîne d'options affiche les données clés des options sur actions de BioXcel Therapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour BioXcel Therapeutics..

BioXcel Therapeutics (NASDAQ:BTAI) Stock, Chaîne d'Options

BIOXCEL THERAPEUTICS INC

BioXcel Therapeutics

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics Inc

News

Press Releases

Synergy Inc. (NASDAQ: SNYR) CEO on Air Spotlights on FOCUSfactor® Legacy, Energy Beverage & Weight Loss – Poised for Explosive Growth – More Stocks Inside

BioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference

Earnings

BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates

BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. "HCW@Home" Series

BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia

Synergy Corp. (NASDAQ: SNYR) 1,600+ Nationwide Store Rollout – PPCB, SNGX, BTAI, HIT + Other Disruptive Stocks Moving Now!

Health Care

General

BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025

BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®

UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®

AMZN

BTAI

COST

IPDN

LPSN

PPCB

PRSO

RMSG

SNGX

SNYR

VTAK

Adicet Bio

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

Clene

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

Cue Biopharma

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Equillium

FibroGen

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

ImmuCell

Immix Biopharma

MiNK Therapeutics

INmune Bio

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

MAIA Biotechnology

MediciNova

NewAmsterdam Pharma Company N.V. - Warrant

NewAmsterdam Pharma Co

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

Lunai Bioworks

Serina Therapeutics

Shattuck Labs

HC Wainwright & Co.

LUCID CAPITAL MARKETS

Rodman & Renshaw

B of A Securities

Canaccord Genuity

Comments

BioXcel Therapeutics

BioXcel Therapeutics (BTAI) Options

BioXcel Therapeutics (NASDAQ:BTAI) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL